DNA hypomethylation mediates immune response in pan-cancer

Plasma Cell-Free Tumor Methylome as a Biomarker in Solid Tumors: Biology and Applications

DNA methylation is a fundamental mechanism of epigenetic control in cells and its dysregulation is strongly implicated in cancer development. Cancers possess an extensively hypomethylated genome with focal regions of hypermethylation at CPG islands. Due to the highly conserved nature of cancer-specific methylation, its detection in cell-free DNA in plasma using liquid biopsies constitutes an area of interest in biomarker research. The advent of next-generation sequencing and newer computational technologies have allowed for the development of diagnostic and prognostic biomarkers that utilize methylation profiling to diagnose disease and stratify risk. Methylome-based predictive biomarkers can determine the response to anti-cancer therapy. An additional emerging application of these biomarkers is in minimal residual disease monitoring. Several key challenges need to be addressed before cfDNA-based methylation biomarkers become fully integrated into practice. The first relates to the biology and stability of cfDNA. The second concerns the clinical validity and generalizability of methylation-based assays, many of which are cancer type-specific. The third involves their practicability, which is a stumbling block for translating technologies from bench to clinic. Future work on developing pan-cancer assays with their respective validities confirmed using well-designed, prospective clinical trials is crucial in pushing for the greater use of these tools in oncology.

Defining high confidence targets of differential CpG methylation in response to in utero arsenic exposure and implications for cancer risk

Arsenic is a relatively abundant metalloid that impacts DNA methylation and has been implicated in various adverse health outcomes including several cancers and diabetes. However, uncertainty remains about the identity of genomic CpGs that are sensitive to arsenic exposure, in utero or otherwise. Here we identified a high confidence set of CpG sites whose methylation is sensitive to in utero arsenic exposure. To do so, we analyzed methylation of infant CpGs as a function of maternal urinary arsenic in cord blood and placenta from geographically and ancestrally distinct human populations. Independent analyses of these distinct populations were followed by combination of results across sexes and populations/tissue types. Following these analyses, we concluded that both sex and tissue type are important drivers of heterogeneity in methylation response at several CpGs. We also identified 17 high confidence CpGs that were hypermethylated across sex, tissue type and population; 11 of these were located within protein coding genes. This pattern is consistent with hypotheses that arsenic increases cancer risk by inducing the hypermethylation of genic regions. This study represents an opportunity to understand consistent, reproducible patterns of epigenomic responses after in utero arsenic exposure and may aid towards novel biomarkers or signatures of arsenic exposure. Identifying arsenic-responsive sites can also contribute to our understanding of the biological mechanisms by which arsenic exposure can affect biological function and increase risk of cancer and other age-related diseases.

Betulinic acid regulates tumor-associated macrophage M2 polarization and plays a role in inhibiting the liver cancer progression

OBJECTIVE

To investigate the regulatory role and mechanism of betulinic acid (BET) in tumor-associated M2 macrophage polarization.

METHODS

For in vitro experiments, RAW246.7 and J774A.1 cells were used, and differentiation of M2 macrophages was induced using recombinant interleukin-4/13. The levels of M2 cell marker cytokines were measured, and the proportion of F4/80+CD206+ cells was evaluated using flow cytometry. Furthermore, STAT6 signaling was detected, and H22 and RAW246.7 cells were cocultured to assess the effect of BET on M2 macrophage polarization. Changes in the malignant behavior of H22 cells after coculturing were observed and a tumor-bearing mouse model was constructed to determine CD206 cell infiltration after BET intervention.

RESULTS

In vitro experiments showed that BET inhibited M2 macrophage polarization and phospho-STAT6 signal modification. Moreover, the ability to promote the malignant behavior of H22 cells was reduced in BET-treated M2 macrophages. Furthermore, in vivo experiments indicated that BET decreased M2 macrophage polarization and infiltration in the microenvironment of liver cancer. BET was noted to predominantly bind to the STAT6 site to inhibit STAT6 phosphorylation.

CONCLUSION

BET bound chiefly to STAT6 to inhibit STAT6 phosphorylation and decrease M2 polarization in the microenvironment of liver cancer. These findings suggest that BET exerts an antitumor effect by modulating M2 macrophage function.